阿司匹林在慢性阻塞性肺疾病患者中获益与风险的研究进展  

Research progress of benefit and risk of Aspirin in patients with chronic obstructive pulmonary disease

作　　者：李萍 王春燕 LI ping;WANG Chun-yan(Department of Pharmacy,Navy No.971 Hospital of People′s Liberation Army,Shangdong Province,Qingdao266071,China)

机构地区：[1]解放军海军第九七一医院药剂科,山东青岛266071

出　　处：《中国当代医药》2020年第22期23-26,共4页China Modern Medicine

摘　　要：阿司匹林作为一种历史悠久的非甾体类抗炎药(NSAIDs),在临床上得到了广泛的应用。阿司匹林哮喘(AIA)是指服用阿司匹林或其他NSAIDs后数分钟或数小时内出现诱发的鼻塞、气喘、支气管痉挛等症状。本文通过查阅相关文献,对阿司匹林用于慢性阻塞性肺疾病患者的获益与风险进行研究,探讨以呼吸困难为主要特征的慢性阻塞性肺疾病患者服用阿司匹林的获益与风险,以期为临床应用提供参考。Aspirin,as a non-steroidal anti-inflammatory drug(NSAIDs)with a long history,has been widely used in clinic.Aspirin asthma(AIA)refers to taking aspirin or other NSAIDs within a few minutes or hours after the occurrence of symptoms such as nasal congestion asthma bronchospasm.In this paper,the benefits and risks of Aspirin in patients with chronic obstructive pulmonary disease were studied by referring to relevant literature,and the benefits and risks of Aspirin in chronic obstructive pulmonary disease patients with respiratory distress as the main characteristics were discussed,so as to provide reference for clinical application.

关 键 词：阿司匹林 阿司匹林哮喘 慢性阻塞性肺疾病 获益与风险 

分 类 号：R56[医药卫生—呼吸系统]